المؤلفون: Maria Cristina Campopiano, R. Michael Tuttle, Paolo Piaggi, Fulvio Basolo, Laura Agate, Luciana Puleo, David Viola, Rossella Elisei, Laura Valerio, Letizia Pieruzzi, Paolo Vitti, Loredana Lorusso, Antonio Matrone, Valeria Bottici, Carlotta Giani, Virginia Cappagli, Liborio Torregrossa, Eleonora Molinaro

المصدر: J Clin Endocrinol Metab

مصطلحات موضوعية: Male, observation, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Thyroid Gland, Biochemistry, microcarcinoma, Endocrinology, Risk Factors, Thyroid cancer, Ultrasonography, Incidence, Incidence (epidemiology), Thyroid, Middle Aged, Online Only, Treatment Outcome, medicine.anatomical_structure, Italy, Practice Guidelines as Topic, outcome, Disease Progression, Thyroidectomy, Female, Radiology, management, Adult, medicine.medical_specialty, differentiated thyroid cancer, Context (language use), Internal medicine, differentiated thyroid cancer, microcarcinoma, active surveillance, management, observation, outcome, medicine, Humans, Thyroid Neoplasms, Watchful Waiting, business.industry, active surveillance, Biochemistry (medical), Disease progression, medicine.disease, Carcinoma, Papillary, Neck ultrasound, Feasibility Studies, Observational study, Lymph Nodes, business, Clinical progression, Follow-Up Studies

الوصف: Context The dramatic rise in the incidence of thyroid cancer over the last 30 years is largely attributable to the increasing diagnosis of papillary microcarcinomas (mPTCs). Current guidelines endorse an observational management approach in properly selected cases. Objective To evaluate the feasibility of active surveillance in mPTC in Italy, its impact on real life, and to identify risk factors of progression. Design and setting In 2014 we started a prospective–observational study of active surveillance in mPTC patients. Patients Included patients demonstrated a single Thy4 or Thy5 thyroid nodule, with largest diameter ≤1.3 cm, and no suspicious laterocervical lymph nodes by neck ultrasonography. Of 185 eligible subjects, 50.3% (93/185) enrolled in the observational management protocol while the others opted for surgery and were excluded from this analysis. Intervention Enrolled patients were followed with neck ultrasound at 6- to 12-month intervals. Disease progression was defined as the appearance of abnormal lymph nodes or nodule enlargement during follow-up. In these cases, patients were directed to surgery. Results Three patients (3/93, 3%) showed clinical progression and required surgery. Another 19 patients (19/93, 20%) decided to transition to surgical intervention even though there was no evidence of disease progression. All operated patients had excellent response to initial treatment despite the delayed surgery. Conclusions Within an Italian medical context, active surveillance appears to be a feasible and safe alternative to immediate surgery in healthy mPTC patients. Only 3% of mPTC demonstrated disease progression during a median follow-up of 19 months (range 6–54) and importantly demonstrated excellent outcomes after surgical intervention in a short-term follow-up.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a21276832fdc4f71f518747b0370fc8Test
https://doi.org/10.1210/clinem/dgz113Test

المؤلفون: Liborio Torregrossa, Cristina Romei, Antonio Matrone, Clara Ugolini, Gabriele Materazzi, Laura Agate, Teresa Ramone, Paolo Piaggi, Carlotta Giani, Rossella Elisei, Eleonora Molinaro, Raffaele Ciampi, Fulvio Basolo

مصطلحات موضوعية: Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, whole tumor capsule, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Thyroid Gland, 030209 endocrinology & metabolism, Context (language use), Carcinoma, Papillary, Follicular, medicine.disease_cause, Biochemistry, Gastroenterology, Papillary thyroid cancer, Thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Follicular phase, Adenocarcinoma, Follicular, medicine, Humans, papillary thyroid cancer, Thyroid Neoplasms, Good outcome, Thyroid cancer, Pathological, Thyroid neoplasm, follicular variant, business.industry, Biochemistry (medical), Middle Aged, medicine.disease, Prognosis, classical variant, Thyroid Cancer, Papillary, 030220 oncology & carcinogenesis, Mutation, Female, business

الوصف: Context Tumor capsule integrity is becoming a relevant issue to predict the biological behavior of human tumors, including thyroid cancer. Objective This work aims to verify whether a whole tumor capsule in the classical variant of papillary thyroid carcinoma (CVPTC) could have as a predictive role of a good outcome as for follicular variant (FVPTC). Methods FVPTC (n = 600) and CVPTC (n = 554) cases were analyzed. We distinguished between encapsulated-FVPTC (E-FVPTC) and encapsulated-CVPTC (E-CVPTC) and, thereafter, invasive (Ei-FVPTC and Ei-CVPTC) and noninvasive (En-FVPTC and En-CVPTC) tumors, according to the invasion or integrity of the tumor capsule, respectively. Cases without a tumor capsule were indicated as invasive-FVPTC (I-FVPTC) and invasive-CVPTC (I-CVPTC). The subgroup of each variant was evaluated for BRAF mutations. Results E-FVPTC was more frequent than E-CVPTC (P Conclusion En-CVPTC is less prevalent than En-FVPTC. However, it has good clinical/ pathological behavior comparable to En-FVPTC. This finding confirms the good prognostic role of a whole tumor capsule in CVPTC as well. New nomenclature for En-CVPTC, similar to that introduced for En-FVPTC (ie, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; NIFTP) could be envisaged.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3dbf78e9ae408a111ff3406b3f2292Test
http://hdl.handle.net/11568/1103062Test

المؤلفون: Giovanni Pellegrini, Laura Agate, Chiara Fustini, Eleonora Molinaro, Paolo Piaggi, Rossella Elisei, David Viola, Valeria Bottici, Cristina Romei, Loredana Lorusso

المساهمون: University of Zurich, Elisei, Rossella

المصدر: Thyroid : official journal of the American Thyroid Association. 31(7)

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Prognostic factor, endocrine system diseases, Adolescent, Endocrinology, Diabetes and Metabolism, Thyroid Gland, 10184 Institute of Veterinary Pathology, Young Adult, Text mining, Endocrinology, Internal medicine, medicine, Biomarkers, Tumor, Doubling time, Brain Stem Neoplasms, Humans, In patient, Antigens, Tumor-Associated, Carbohydrate, Thyroid Neoplasms, Aged, business.industry, Medullary thyroid cancer, Middle Aged, medicine.disease, Prognosis, 1310 Endocrinology, Diabetes and Metabolism, Survival Rate, 2712 Endocrinology, Diabetes and Metabolism, Response Evaluation Criteria in Solid Tumors, Calcitonin, Disease Progression, 570 Life sciences, biology, CA19-9, Female, business

الوصف: Background: Serum Ca19.9 positivity is a prognostic factor for mortality in patients with advanced medullary thyroid cancer (aMTC), independently from calcitonin doubling time (DT). However, it is ...

وصف الملف: thy.2020.0060.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fee3d3d64af302185bb8703303e38f2bTest
https://pubmed.ncbi.nlm.nih.gov/33234054Test

المؤلفون: Elisa Minaldi, Alberto Ragni, Eleonora Molinaro, Alessandro Piovesan, Alice Nervo, Carlotta Giani, Laura Valerio, Alessandro Prete, Rossella Elisei, Laura Agate, Antonio Matrone

المصدر: Journal of endocrinological investigation. 44(10)

مصطلحات موضوعية: Oncology, Calcitonin, Adult, Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Salvage therapy, 030209 endocrinology & metabolism, Antineoplastic Agents, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Stable Disease, Internal medicine, medicine, Biomarkers, Tumor, Lenvatinib, Humans, In patient, Thyroid Neoplasms, Carcinoembrionic antigen, Medullary thyroid cancer, Tyrosine kinase inhibitors, Aged, Salvage Therapy, business.industry, Phenylurea Compounds, Middle Aged, medicine.disease, Prognosis, Carcinoma, Neuroendocrine, Survival Rate, chemistry, 030220 oncology & carcinogenesis, Case-Control Studies, Quinolines, Dose reduction, Female, business, Progressive disease, Follow-Up Studies

الوصف: Patients with advanced progressive metastatic medullary thyroid cancer (MTC), show poor prognosis and few available systemic therapeutic options. After the loss of clinical benefit with other tyrosine kinase inhibitors (TKI), we evaluated the use of lenvatinib as salvage therapy. Ten patients who experienced the loss of clinical benefit after treatment with at least one previous TKI, were treated with lenvatinib. We assessed patient’s response immediately before, at the first (first-EV) and last (last-EV) evaluation, after the beginning of treatment. At first-EV, one patient died, while all the remaining 9 showed a stable disease (SD) in the target lesions. At last-EV, SD was still observed in seven patients, while partial response (PR) and progressive disease (PD), in one patient each. Conversely, analyzing all target and non-target lesions, at first-EV, we observed PR in one patient and SD in eight patients. At last-EV, PR was shown in two patients and SD was shown in seven. Bone metastases showed stable disease control at both first-EV and last-EV in only approximately 60% of cases. Tumor markers (CTN and CEA) decreased at first-EV, while they increased at last-EV. Seven patients experienced at least one dose reduction during treatment with lenvatinib. In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfbe519f85ff008a427b4016613675f0Test
https://pubmed.ncbi.nlm.nih.gov/34089498Test

المؤلفون: Adele Caldarella, Rossella Elisei, Francesca Bianchi, Virginia Cappagli, Gianfranco Manneschi, Eleonora Molinaro, Valeria Bottici, Laura Agate, Paolo Piaggi

المصدر: International journal of cancerREFERENCES. 147(10)

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Urinary system, Population, Cohort Studies, Iodine Radioisotopes, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Risk Factors, Internal medicine, thyroid cancer, Medicine, Humans, radioiodine treatment, second primary cancer, Thyroid Neoplasms, education, Child, Thyroid cancer, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Incidence (epidemiology), Incidence, Radioiodine therapy, Neoplasms, Second Primary, Second primary cancer, Middle Aged, medicine.disease, Oncology, Italy, 030220 oncology & carcinogenesis, Cohort, Lifetime risk, Female, business

الوصف: The long-term survival of differentiated thyroid cancer (DTC) patients and the need to perform several treatments with radioiodine (131-I) lead to the question if the lifetime risk of developing a nonthyroidal second primary cancer (NTSPC) is increased in these patients. In our study, we assessed the prevalence of NTSPCs in thyroid cancer population and evaluated the possible causative role of 131-I treatment. We analyzed 1096 consecutive patients followed at our institution from 1964 to 1998. A total of 101 NTSPCs were observed in 92/1096 patients (8.4%) among which 17/101 (16.8%) diagnosed before DTC and 84/101 (83.2%) diagnosed after. The most frequent tumor sites observed were breast and bladder/urinary tract in the post-DTC group and breast and hematological system in the pre-DTC group. Regarding 131-I treatment, we did not observe any significant differences regarding either the number of treatments or the cumulative activity. The only significant parameter associated with an increased incidence of NTSPC was follow-up (P = .02): a longer follow-up period was associated with a higher number of NTSPCs. The mean latency between 131-I and NTSPC was 10.52 ± 7.69 years. Comparing with the general Italian population, independent of radioiodine treatment, the standard incidence ratio in our cohort was similar to that of the general population (SIR 1.07) and this result was confirmed by analyzing only the treated group. In conclusion, these results show that the risk of NTSPCs in the DTC patients' population is similar to that in the general population and 131-I treatment was not associated with an increased risk.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d9f843166dd8606dd7d68cdddd4c3e9Test
https://pubmed.ncbi.nlm.nih.gov/32449158Test

المؤلفون: Rossella Elisei, David Viola, Alessia Tacito, Virginia Cappagli, Antonio Matrone, Raffaele Ciampi, Teresa Ramone, Valeria Bottici, Paolo Piaggi, Cristina Romei, Laura Valerio, Eleonora Molinaro, Laura Agate

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, vandetanib, Adolescent, medicine.drug_class, Endocrinology, Diabetes and Metabolism, ECOG Performance Status, Vandetanib, Gastroenterology, Tyrosine-kinase inhibitor, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Piperidines, Medullary thyroid cancer, vandetanib, Internal medicine, Carcinoma, Medicine, Humans, Progression-free survival, Thyroid Neoplasms, Young adult, Adverse effect, Aged, Medullary thyroid cancer, business.industry, Middle Aged, medicine.disease, Carcinoma, Neuroendocrine, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Quinazolines, Female, business, medicine.drug

الوصف: Vandetanib is an important treatment option for advanced metastatic medullary thyroid cancer. The aims of this study were to evaluate the predictors of both a longer response to vandetanib and the outcome. Medical records of 79 medullary thyroid cancer patients treated with vandetanib at our center were analysed. Twenty-five patients were treated for

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb4d60c57ca00f2539e9ce101234470dTest
https://hdl.handle.net/11568/1015758Test

المؤلفون: Paolo Piaggi, David Viola, Rossella Elisei, Eleonora Molinaro, Valeria Bottici, Laura Agate, Maria Cristina Campopiano, Francesca Bianchi, Debora Podestà, Luciana Puleo, Laura Valerio, Antonio Matrone, Loredana Lorusso, Carlotta Giani, Virginia Cappagli

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Thyrotropin, Gastroenterology, Iodine Radioisotopes, 0302 clinical medicine, Endocrinology, QUALITY-OF-LIFE, ASSOCIATION GUIDELINES, HUMAN THYROTROPIN, Neoplasm Metastasis, Young adult, Child, Thyroid cancer, Lymph node, Aged, 80 and over, General Medicine, Middle Aged, RADIOACTIVE IODINE THERAPY, Combined Modality Therapy, Recombinant Proteins, Treatment Outcome, medicine.anatomical_structure, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Thyroidectomy, Female, Adult, medicine.medical_specialty, Adolescent, CARCINOMA, 030209 endocrinology & metabolism, THYROXINE WITHDRAWAL, Adenocarcinoma, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Thyroid Neoplasms, Propensity Score, RADIOIODINE ABLATION, STIMULATING HORMONE, DISTANT METASTASES, TASK-FORCE, Aged, Retrospective Studies, Chemotherapy, business.industry, Case-control study, Retrospective cohort study, medicine.disease, Case-Control Studies, business, Follow-Up Studies

الوصف: Objective: At present, recombinant TSH cannot be used for the treatment of metastatic differentiated thyroid cancer patients. The aim of this study was to evaluate if the type of TSH stimulation, recombinant or endogenous, had an impact on the outcome of these patients. Design and methods: We compared the outcome of two propensity score-matched groups of metastatic patients, stimulated by either only recombinant TSH (n = 43) or only endogenous TSH (n = 34). Results: As expected from the matching procedure, the clinical–pathological features and the cumulative 131-I activities administered to the two groups were very similar. After 4 years of follow-up, 4% of patients were cured, 3% had biochemical disease and 93% had structural disease. However, 91% of patients obtained a clinical benefit from this therapy in terms of stabilization of the disease or complete remission or partial response. When considering the two groups separately, we did not find any difference in their outcome. When considering the response to 131-I therapy of the single type of metastases, 8% of lymph node metastases and 8% of lung metastases disappeared but none of the bone metastases. The response to 131-I therapy of the single type of metastases was similar when we looked at the two groups separately. Conclusions: This study shows (i) an overall clinical benefit of the 131-I therapy, since the majority of patients remained affected but with a stable disease, and (ii) that the preparation with either recombinant or endogenous TSH has no impact on the 131-I therapy efficacy and the outcome of our two groups of patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a08809077517b623ab39d62cc70a2b7Test
http://hdl.handle.net/11568/1049363Test

المؤلفون: Cristina Campopiano, Rossella Elisei, Eleonora Molinaro, Raffaele Ciampi, Teresa Ramone, Valeria Bottici, Alessandro Prete, Laura Valerio, Cristina Romei, David Viola, Carlotta Giani, Virginia Cappagli, Antonio Matrone, Laura Agate, Loredana Lorusso, Alessia Tacito

المصدر: Genes, Vol 10, Iss 9, p 698 (2019)
Genes
Volume 10
Issue 9

مصطلحات موضوعية: Male, endocrine system diseases, lcsh:QH426-470, Multiple Endocrine Neoplasia Type 2a, 030209 endocrinology & metabolism, medicine.disease_cause, Proto-Oncogene Mas, Article, Germline, Thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Unknown Significance, Germline mutation, Mutation Rate, medullary thyroid carcinoma, Genetics, medicine, Humans, Clinical significance, Thyroid Neoplasms, Germ-Line Mutation, Genetics (clinical), Mutation, genetic screening, RET, VUS, business.industry, Proto-Oncogene Proteins c-ret, Large series, lcsh:Genetics, Carcinoma, Medullary, 030220 oncology & carcinogenesis, Cohort, Female, business

الوصف: Background: Pathogenic germline mutations affecting the RET proto-oncogene underlie the development of hereditary medullary thyroid carcinoma (MTC). The aims of this study were to evaluate the prevalence of germline RET mutations in a large series of MTC, collected over the last 25 years, and to reappraise their clinical significance. Methods: We performed RET genetic screening in 2031 Italian subjects: patients who presented with sporadic (n = 1264) or hereditary (n = 117) MTC, plus 650 relatives. Results: A RET germline mutation was found in 115/117 (98.3%) hereditary and in 78/1264 (6.2%) apparently sporadic cases: in total, 42 distinct germline variants were found. The V804M mutation was the most prevalent in our cohort, especially in cases that presented as sporadic, while mutations affecting cysteine residues were the most frequent in the group of clinically hereditary cases. All M918T mutations were &ldquo
de novo&rdquo
and exclusively associated with MEN2B. Several variants of unknown significance (VUS) were also found. Conclusions: a) RET genetic screening is informative in both hereditary and sporadic MTC
b) the prevalence of different mutations varies with V804M being the most frequent
c) the association genotype&ndash
phenotype is confirmed
d) by RET screening, some VUS can be found but their pathogenic role must be demonstrated before screening the family.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::907bf09cc18ae61903935b2f2b0938f6Test
https://www.mdpi.com/2073-4425/10/9/698Test

المؤلفون: Laura Valerio, David Viola, Francesco Latrofa, Carlotta Giani, Eleonora Molinaro, Clara Ugolini, Valeria Bottici, Virginia Cappagli, Antonio Matrone, Rossella Elisei, Fulvio Basolo, Gabriele Materazzi, Laura Agate, Liborio Torregrossa, Cristina Romei

المصدر: The Journal of clinical endocrinology and metabolism. 104(7)

مصطلحات موضوعية: 0301 basic medicine, Thyroid nodules, Adult, Calcitonin, medicine.medical_specialty, Pediatrics, Delayed Diagnosis, Time Factors, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Adrenal Gland Neoplasms, Disease, Multiple Endocrine Neoplasia Type 2b, Pheochromocytoma, Biochemistry, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, medicine, Carcinoma, Humans, Thyroid Neoplasms, Child, business.industry, Biochemistry (medical), Medullary thyroid cancer, medicine.disease, MEN 2B syndrome, Carcinoma, Neuroendocrine, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Female, business, Multiple endocrine neoplasia type 2b

الوصف: Background Multiple endocrine neoplasia type 2B (MEN 2B) is a very rare syndrome characterized by a very peculiar phenotype with mucosal neuromas, marfanoid habitus, and bumpy lips associated with medullary thyroid cancer (MTC) and pheochromocytoma (PHEO). Although the syndrome was first described 50 years ago, it is still diagnosed too late, when the MTC is metastatic and frequently when the PHEO has already developed. Case presentations We report on two cases of MEN 2B that were diagnosed too late, preventing a cure. The cases involve two females who were 25 and 12 years old. Both were previously treated for congenital skeletal abnormalities; however, despite their bumpy lips and mucosal neuromas, MEN 2B syndrome was not recognized. When they arrived at our center for both the presence of thyroid nodules and elevated serum calcitonin values, the MTC was already metastatic, and the older patient had already developed a bilateral PHEO. After 3 years and 1 year of follow-up, the two patients are still alive but with persistent structural and biochemical disease. Discussion These two cases show that knowledge of this syndrome is still insufficient and that the lack of knowledge impairs the ability to obtain an early diagnosis and cure. Because most patients with MEN 2B have no familial history, the only way to ensure a timely diagnosis is to recognize the MEN 2B phenotype on a clinical basis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ff0d101cf1d83a4653a7893cedad9bTest
https://pubmed.ncbi.nlm.nih.gov/30597074Test

المؤلفون: Antonio, Matrone, Francesco, Latrofa, Liborio, Torregrossa, Paolo, Piaggi, Carla, Gambale, Alessio, Faranda, Debora, Ricci, Laura, Agate, Eleonora, Molinaro, Fulvio, Basolo, Paolo, Vitti, Rossella, Elisei

مصطلحات موضوعية: Adult, Male, Lymphocytic thyroiditis, Radioiodine ablation, Thyroid Gland, Thyroglobulin antibodies, Middle Aged, Thyroid Function Tests, Differentiated thyroid cancer, Thyroglobulin, Carcinoma, Papillary, Diabetes and Metabolism, Young Adult, Treatment Outcome, Endocrinology, Diabetes and Metabolism, Endocrinology, Thyroidectomy, Humans, Female, Thyroid Neoplasms, Aged, Autoantibodies

الوصف: Thyroglobulin (Tg) antibodies (TgAb) can interfere with Tg measurement and can be used as "Tg surrogate" in patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy (TTx) and radioiodine remnant ablation (RRA). In contrast, few data, and in patients usually followed for a short-term follow-up, have been reported about the changes of TgAb levels in patients treated with TTx but without RRA. The aims of this study were to evaluate the changes of TgAb levels in DTC patients treated with TTx but not RRA and to identify the factors that influence these changes.The change in TgAb levels in 107 DTC (1 cm) patients submitted to TTx but not RRA was evaluated. Patients were followed for a median of 6.3 years, and all had at least three determinations of TgAb and neck ultrasound (nUS).TgAb levels showed a progressive decrease during follow-up. Initial TgAb levels and degree of lymphocytic infiltration influenced the time but not the rate of TgAb disappearance. No influence on time and rate of the decrease in TgAb was observed when the association with thyroperoxidase antibodies (TPOAb) levels were considered. A TgAb cutoff value of 61.9 IU/mL at first postoperative evaluation was a good indicator for disappearance of the TgAb within six years. No tumor recurrence was observed in the series. In one case, the progressive increase in TgAb anticipated the reappearance of benign thyroid tissue with lymphocytic infiltration.TgAb levels decline in the majority of DTC patients treated with TTx but not ablated with radioiodine. The levels decrease rapidly after the surgical treatment and continue to decrease over time. The time of disappearance is influenced by the initial TgAb levels and the degree of lymphocytic infiltration. No influence of the actual TPOAb levels has been observed. An increase in TgAb levels should not be overlooked, since it can indicate the presence or reappearance of either normal thyroid tissue or tumor recurrence.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7285fd6daa2bb80e47a2a119f53ce32dTest
http://hdl.handle.net/11568/939715Test